Karyopharm Therapeutics, Inc. (KPTI)
| Market Cap | 453.48M |
| Revenue (ttm) | 234.23M |
| Net Income (ttm) | -108.07M |
| Shares Out | 79.42M |
| EPS (ttm) | -1.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,673,883 |
| Open | 5.62 |
| Previous Close | 5.46 |
| Day's Range | 5.50 - 5.79 |
| 52-Week Range | 4.42 - 14.73 |
| Beta | -0.33 |
| Analysts | Buy |
| Price Target | 12.35 (+116.3%) |
| Earnings Date | May 5, 2022 |
About KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with...
Financial Performance
In 2021, KPTI's revenue was $209.82 million, an increase of 94.12% compared to the previous year's $108.09 million. Losses were -$124.09 million, -36.78% less than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price forecast is 12.35, which is an increase of 116.29% from the latest price.
News
Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hyb...
SHANGHAI and HONG KONG , May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to disc...
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Cong...
NEWTON, Mass. , May 12, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that initial data f...
Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference
NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's ...
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 15.87% and 37.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – – XPOVIO® (selinexor) Net Product Revenue of $28....
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , May 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that in connection w...
Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022
-- Conference Call Scheduled for Thursday, May 5, 2022, at 8:30 a.m. ET -- NEWTON, Mass.
Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting
NEWTON, Mass. , April 27, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that four abstract...
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm to Participate at the Canaccord Genuity Horizons in Oncology Conference
NEWTON, Mass. , April 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's...
Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appo...
- Formerly of Aravive, Genmab and Merck & Co., Dr. Rangwala will Lead Karyopharm's Clinical Development Programs and Strategy - - As Part of Karyopharm's Evolution, Co-Founders Dr. Shacham and Dr. Kauff...
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurre...
Study Results to be Presented at the European Society of Medical Oncology's Virtual Plenary and the Society for Gynecologic Oncology 2022 Annual Meeting on Women's Cancer Company to Host Investor Confe...
Karyopharm Names New Head of Investor Relations
– Elhan Webb, CFA, Formerly of Rubius Therapeutics and Radius Health, Appointed as Senior Vice President of Investor Relations – – Webb Brings More than 20 Years of Diverse International Experience Acro...
Karyopharm to Participate at the Barclays Global Healthcare Conference
NEWTON, Mass. , March 9, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's...
Why Are Karyopharm Shares Trading Lower Today
Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock plunged after an update on its supplemental New Drug Application submission based on the Phase 3 SIENDO study data of selinexor as front-line maintenance...
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer
NEWTON, Mass., March 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today provided an update on its disc...
Here's Why Karyopharm Therapeutics Is Sliding on Tuesday
Investors aren't pleased with the surprise departure of the company's chief medical officer.
Why Are Karyopharm Shares Plunging Today?
Karyopharm Therapeutics Inc (NASDAQ: KPTI) revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities." While CEO Paulson looks for Shah's ...
Karyopharm Announces Changes to Its Clinical Leadership Team
NEWTON, Mass., Feb. 22, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clini...
Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference
NEWTON, Mass., Feb. 11, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulso...
Why Karyopharm Therapeutics Stock Was a Winner on Wednesday
An analyst upgrade that followed much better-than-expected quarterly results put some real zip into the biotech's stock.
Why Karyopharm Therapeutics Stock Is Falling Today
Fourth-quarter sales of Xpovio were encouraging, but top-line results from another trial were a little disappointing.
Karyopharm Therapeutics (KPTI) Tops Q4 Earnings and Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 215% and 125.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage pharmaceutical company pioneering novel cancer t...
Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progressi...
NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line re...